Point72 Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-3
Closed -$195 2958
2023
Q3
$195 Sell
3
-197
-99% -$18.5K ﹤0.01% 2383
2023
Q2
$20.4K Sell
200
-205
-51% -$28.2K ﹤0.01% 1782
2023
Q1
$71.7K Buy
+405
New +$136K ﹤0.01% 1700
2022
Q2
Sell
-12,753
Closed -$5.58M 1692
2022
Q1
$5.58M Buy
12,753
+2,800
+28% +$1.15M 0.02% 672
2021
Q4
$4.36M Buy
+9,953
New +$5M 0.02% 703
2020
Q1
Sell
-2,311
Closed -$1.34M 1136
2019
Q4
$1.34M Sell
2,311
-1,914
-45% -$1.34M 0.01% 676
2019
Q3
$2.78M Buy
+4,225
New +$3.51M 0.02% 551
2019
Q2
Sell
-2,537
Closed -$1.79M 1578
2019
Q1
$1.79M Buy
+2,537
New +$1.52M 0.01% 713
2017
Q3
Sell
-694
Closed -$385K 1091
2017
Q2
$385K Buy
+694
New +$440K ﹤0.01% 777
2016
Q1
Sell
-14,728
Closed -$8.94M 876
2015
Q4
$8.94M Buy
14,728
+14,039
+2,038% +$7.71M 0.07% 308
2015
Q3
$354K Sell
689
-697
-50% -$467K ﹤0.01% 668
2015
Q2
$606K Buy
+1,386
New +$536K ﹤0.01% 635

Other funds holding TVRD

Point72 Asset Management's TVRD Position: Q4 2023 in Review

Point72 Asset Management sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 3 shares — an estimated $195 sold.

Point72 Asset Management first reported a position in TVRD in Q2 2015 and held it in 12 quarters. The position peaked at $8.94M in Q4 2015. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

  • Point72 Asset Management reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Asset Management sold 3 Tvardi Therapeutics shares in Q4 2023, an estimated $195.
  • Point72 Asset Management first reported a position in Tvardi Therapeutics in Q2 2015 and held it in 12 quarters.
  • Point72 Asset Management's Tvardi Therapeutics position peaked at $8.94M in Q4 2015.
  • 109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.